Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump
HELP•Helus Pharma said its experimental drug HLP003 significantly improved depression symptoms versus placebo in a late-stage study of 222 adults; its US-listed shares rose more than 20% in premarket trading.
1. Late-stage study results
Helus Pharma said HLP003 improved depression symptoms by 19.5 points on a standard scale after six weeks, compared with 11.9 points for placebo. The benefit appeared as early as two days after treatment and lasted through 12 weeks.
2. Response and remission
After six weeks, 56.3% of patients receiving HLP003 had symptoms cut by at least half, versus 28.2% on placebo. Remission rates were 50.9% and 18.2%, respectively. The trial enrolled 222 adults with moderate to severe depression, all of whom continued their usual antidepressants.
3. Safety and next study
Helus said HLP003 was generally well tolerated, with most side effects mild to moderate and occurring on the day of dosing. The company recorded three treatment-related serious adverse events but identified no new safety signals. It plans a second study, with results expected in late 2027.




